Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
MM

Michael Mark — 49 Patents

BOBOE: 43 patents #307 of 12,373Top 3%
DGDr. Karl Thomae Gmbh: 4 patents #59 of 181Top 35%
KGKarl Thomae Gmbh: 2 patents #31 of 87Top 40%
Biberach an der Riß, DE: #9 of 243 inventorsTop 4%
Overall (All Time): #55,592 of 4,157,543Top 2%
49 Patents All Time
Michael Mark has been granted 49 US patents while listed as an inventor at BOE. The first was granted in 1991 and the most recent in May 2025. Michael Mark ranks #55,592 of 4,157,543 US inventors in our database (top 1.3%). Patent records list Michael Mark in Biberach an der Riß, DE.

Issued Patents All Time

Showing 1–25 of 49 patents

Patent #TitleCo-InventorsDate
12312352 Use of a DPP-4 inhibitor in SIRS and/or sepsis Thomas KLEIN, Andreas DAIBER, Klaus Dugi, Thomas MUENZEL 2025-05-27
12171767 Uses of DPP IV inhibitors Klaus Dugi, Frank Himmelsbach 2024-12-24
12115179 Pharmaceutical composition, methods for treating and uses thereof Peter Eickelmann, Leo John SEMAN, Leo Thomas, Uli Christian BROEDL, Rolf GREMPLER 2024-10-15
11911388 Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug Eva Ulrike GRAEFE-MODY, Thomas KLEIN, Hans-Juergen WOERLE 2024-02-27
11911387 Vasoprotective and cardioprotective antidiabetic therapy Thomas KLEIN, Andreas DAIBER, Odd-Erik JOHANSEN, Sanjaykumar PATEL, Hans-Juergen WOERLE 2024-02-27
11291668 Uses of DPP IV inhibitors Klaus Dugi, Frank Himmelsbach 2022-04-05
10406172 Pharmaceutical composition, methods for treating and uses thereof Peter Eickelmann, Leo John SEMAN, Leo Thomas, Uli Christian BROEDL, Rolf GREMPLER 2019-09-10
10195203 Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome Thomas KLEIN, Maximilian von EYNATTEN 2019-02-05
10092571 Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin Klaus Dugi, Eva Ulrike GRAEFE-MODY, Hans-Juergen WOERLE, Heike ZIMDAHL-GELLING 2018-10-09
10080754 Uses of DPP IV inhibitors Klaus Dugi, Frank Himmelsbach 2018-09-25
10004747 Combination therapy Thomas KLEIN, Rolf GREMPLER 2018-06-26
9713618 Method for modifying food intake and regulating food preference with a DPP-4 inhibitor Thomas KLEIN 2017-07-25
9603851 Combination therapy Thomas KLEIN, Rolf GREMPLER 2017-03-28
9556175 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions Frank Himmelsbach, Elke Langkopf, Matthias Eckhardt, Roland Maier, Ralf Lotz +1 more 2017-01-31
9526730 Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome Thomas KLEIN, Maximilian von EYNATTEN, Berthold Hocher, Yuliya SHARKOVSKA 2016-12-27
9457029 Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin Klaus Dugi, Eva Ulrike GRAEFE-MODY, Hans-Juergen WOERLE, Heike ZIMDAHL-GELLING 2016-10-04
9321791 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions Frank Himmelsbach, Elke Langkopf, Matthias Eckhardt, Roland Maier, Ralf Lotz +1 more 2016-04-26
9186392 Combination therapy Thomas KLEIN, Rolf GREMPLER 2015-11-17
9173859 Uses of DPP IV inhibitors Klaus Dugi, Frank Himmelsbach 2015-11-03
9149478 Diabetes therapy Thomas KLEIN, Leo Thomas 2015-10-06
9034883 Vasoprotective and cardioprotective antidiabetic therapy Thomas KLEIN, Andreas DAIBER, Odd-Eric JOHANSEN, Sanjaykumar PATEL, Hans-Juergen WOERLE 2015-05-19
8673927 Uses of DPP-IV inhibitors Klaus Dugi, Frank Himmelsbach 2014-03-18
8664232 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions Frank Himmelsbach, Elke Langkopf, Matthias Eckhardt, Roland Maier, Ralf Lotz +1 more 2014-03-04
8551957 Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate Klaus Dugi, Leo Thomas, Frank Himmelsbach 2013-10-08
8513264 Combination therapy for the treatment of diabetes and related conditions Peter Eickelmann, Gerd LUIPPOLD, Leo Thomas 2013-08-20